Reply to Walker et al

Samer S. El-Kamary; Mohamed Hashem; Ravi Jhaveri; Hesham El-Ghazaly

doi:10.1093/cid/ciy240

Reply to Walker et al

Samer S. El-Kamary^*, Mohamed Hashem, Ravi Jhaveri, Hesham El-Ghazaly

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	984
Number of pages	1
Journal	Clinical Infectious Diseases
Volume	67
Issue number	6
DOIs	https://doi.org/10.1093/cid/ciy240
State	Published - Aug 31 2018

Funding

R. J., and H. E. received grants from the US-Egypt Science and Technology Joint Fund and the Merck Investigator Studies Program. R. J. also notes grants from Gilead, AbbVie, MedImmune, GenMark, Alios, and Merck, as well as consultancy fees from AbbVie and MedImmune. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciy240

Cite this

@article{3aaf434422f545e3a91f655af0e3fda2,

title = "Reply to Walker et al",

author = "El-Kamary, {Samer S.} and Mohamed Hashem and Ravi Jhaveri and Hesham El-Ghazaly",

note = "Funding Information: R. J., and H. E. received grants from the US-Egypt Science and Technology Joint Fund and the Merck Investigator Studies Program. R. J. also notes grants from Gilead, AbbVie, MedImmune, GenMark, Alios, and Merck, as well as consultancy fees from AbbVie and MedImmune. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.",

year = "2018",

month = aug,

day = "31",

doi = "10.1093/cid/ciy240",

language = "English (US)",

volume = "67",

pages = "984",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Reply to Walker et al

AU - El-Kamary, Samer S.

AU - Hashem, Mohamed

AU - Jhaveri, Ravi

AU - El-Ghazaly, Hesham

N1 - Funding Information: R. J., and H. E. received grants from the US-Egypt Science and Technology Joint Fund and the Merck Investigator Studies Program. R. J. also notes grants from Gilead, AbbVie, MedImmune, GenMark, Alios, and Merck, as well as consultancy fees from AbbVie and MedImmune. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

PY - 2018/8/31

Y1 - 2018/8/31

UR - http://www.scopus.com/inward/record.url?scp=85055002974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055002974&partnerID=8YFLogxK

U2 - 10.1093/cid/ciy240

DO - 10.1093/cid/ciy240

M3 - Letter

C2 - 29617734

AN - SCOPUS:85055002974

SN - 1058-4838

VL - 67

SP - 984

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Reply to Walker et al

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this